ArticleJAMA dermatology2016
Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity.
Article in JAMA dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- A genome-wide cross-trait analysis identifies shared loci and causal relationships of obesity and lipidemic traits with psoriasis.Frontiers in immunology · 2024Pooled it
- Association between psoriasis and lung cancer: two-sample Mendelian randomization analyses.BMC pulmonary medicine · 2023Pooled it
- Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies.European journal of epidemiology · 2018Pooled it
- Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Trial
- Psoriasis risk in patients with diabetic retinopathy: A nationwide population-based study.Scientific reports · 2018Trial
- Methodological considerations for strengthening evidence on CKM health and psoriasis risk.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Assessing the association of type 2 diabetes with skin health status: a study of the Northern Finland Birth Cohort 1966.BMJ open · 2026Article
- Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2.Dermatology and therapy · 2026Article
- Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography.Dermatology and therapy · 2026Article
- Association Between Psoriasis Risk and Body Mass Index and Waist Circumference in Diabetes: A Population-Based Cohort Study.Annals of dermatology · 2026Article
- Associations Between Psoriasis and Endocrine Diagnoses in a Tertiary-Center Electronic Health Record Database: A Cross-Sectional Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Deep cardiac phenotyping by cardiovascular magnetic resonance reveals subclinical focal and diffuse myocardial injury in patients with psoriasis (PSOR-COR study).Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Gout, Hyperuricemia and Psoriatic Arthritis: An Evolving Conundrum.Current rheumatology reports · 2025Review
- Risk of Head and Neck Cancer in Patients with Psoriasis: A Nationwide Population-based Study.Acta dermato-venereologica · 2024Article
- Discontinuation of Fumaric Acid Esters is Affected by Depressive Symptomatology: A Retrospective Analysis.Acta dermato-venereologica · 2024Article
- Associations between body mass index and all-cause mortality among individuals with psoriasis: results from the NHANES database retrospective cohort study.Frontiers in nutrition · 2024Article
- Infections in psoriatic arthritis: association with treatment.Therapeutic advances in musculoskeletal disease · 2024Review
- Weight loss improves inflammation by T helper 17 cells in an obese patient with psoriasis at high risk for cardiovascular events.Journal of diabetes investigation · 2023Article
- Review
- COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study.Frontiers in immunology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importancePsoriasis has been shown to be associated with overweight and type 2 diabetes mellitus. The genetic association is unclear.
objectiveTo examine the association among psoriasis, type 2 diabetes mellitus, and body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) in twins. DESIGN, SETTING, AND
participantsThis cross-sectional, population-based twin study included 34 781 Danish twins, 20 to 71 years of age. Data from a questionnaire on psoriasis was validated against hospital discharge diagnoses of psoriasis and compared with hospital discharge diagnoses of type 2 diabetes mellitus and self-reported BMI. Data were collected in the spring of 2002. Data were analyzed from January 1 to October 31, 2014. MAIN OUTCOMES AND MEASURES: Crude and adjusted odds ratios (ORs) were calculated for psoriasis in relation to type 2 diabetes mellitus, increasing BMI, and obesity in the whole population of twins and in 449 psoriasis-discordant twins. Variance component analysis was used to measure genetic and nongenetic effects on the associations.
resultsAmong the 34 781 questionnaire respondents, 33 588 with complete data were included in the study (15 443 men [46.0%]; 18 145 women [54.0%]; mean [SD] age, 44.5 [7.6] years). After multivariable adjustment, a significant association was found between psoriasis and type 2 diabetes mellitus (odds ratio [OR], 1.53; 95% CI, 1.03-2.27; P = .04) and between psoriasis and increasing BMI (OR, 1.81; 95% CI, 1.28-2.55; P = .001 in individuals with a BMI>35.0). Among psoriasis-discordant twin pairs, the association between psoriasis and obesity was diluted in monozygotic twins (OR, 1.43; 95% CI, 0.50-4.07; P = .50) relative to dizygotic twins (OR, 2.13; 95% CI, 1.03-4.39; P = .04). Variance decomposition showed that additive genetic factors accounted for 68% (95% CI, 60%-75%) of the variance in the susceptibility to psoriasis, for 73% (95% CI, 58%-83%) of the variance in susceptibility to type 2 diabetes mellitus, and for 74% (95% CI, 72%-76%) of the variance in BMI. The genetic correlation between psoriasis and type 2 diabetes mellitus was 0.13 (-0.06 to 0.31; P = .17); between psoriasis and BMI, 0.12 (0.08 to 0.19; P < .001). The environmental correlation between psoriasis and type 2 diabetes mellitus was 0.10 (-0.71 to 0.17; P = .63); between psoriasis and BMI, -0.05 (-0.14 to 0.04; P = .44). CONCLUSIONS AND RELEVANCE: This study determines the contribution of genetic and environmental factors to the interaction between obesity, type 2 diabetes mellitus, and psoriasis. Psoriasis, type 2 diabetes mellitus, and obesity are also strongly associated in adults after taking key confounding factors, such as sex, age, and smoking, into account. Results indicate a common genetic etiology for psoriasis and obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.